BiotechTube
Bristol Myers Squibb

Bristol Myers Squibb

BMY
United States

Bristol Myers Squibb operates as a premier global biopharmaceutical company with a mission to transform patients' lives through science. The company maintains leadership positions in oncology, hematology, cardiovascular, and immunology therapeutic areas with blockbuster products and innovative treatment modalities. BMS employs a research strategy rooted in causal human biology and diverse platform technologies to deliver first- and best-in-class medicines to patients worldwide.

bms.com

BMY · Stock Price

USD 57.391.82 (-3.07%)
Market Cap: $119.6B

Historical price data

AI Company Overview

Bristol Myers Squibb operates as a premier global biopharmaceutical company with a mission to transform patients' lives through science. The company maintains leadership positions in oncology, hematology, cardiovascular, and immunology therapeutic areas with blockbuster products and innovative treatment modalities. BMS employs a research strategy rooted in causal human biology and diverse platform technologies to deliver first- and best-in-class medicines to patients worldwide.

OncologyHematologyCardiovascularImmunologyNeuroscience

Technology Platform

Multi-platform biopharmaceutical company leveraging cell therapy, targeted protein degradation, radiopharmaceuticals, advanced small molecules, biotherapeutics, and antibody-drug conjugates based on causal human biology.

Pipeline

1000
1000 drugs in pipeline334 in Phase 3
DrugIndicationStageWatch
Abatacept + PlaceboActive Rheumatoid ArthritisPhase 3
MuraglitazarDiabetes, Type 2Phase 3
Subcutaneous(SC) Abatacept + MethotrexateRheumatoid Arthritis (RA)Phase 3
DeucravacitinibSystemic Lupus ErythematosusPhase 3
Peginterferon Lambda-1a + Peginterferon Alfa-2a + Ribavirin ...Hepatitis C VirusPhase 3

Opportunities

BMS has significant growth opportunities through its innovative pipeline in protein degradation, expanding CAR-T therapy applications, and geographic expansion in emerging markets.
The company's diverse platform technologies position it well to address multiple therapeutic areas with high unmet medical need.

Risk Factors

Key risks include patent expiries for major revenue-generating products like Revlimid, intense competition in oncology markets, and ongoing pricing pressure from healthcare systems globally.
Clinical trial execution and regulatory approval timelines also present ongoing risks to pipeline value.

Competitive Landscape

BMS competes with major pharmaceutical companies including Roche, Merck, Pfizer, and J&J in oncology and other therapeutic areas. The company differentiates through its leading immuno-oncology franchise, innovative CAR-T platform, and next-generation protein degradation technologies.